Clovis Oncology Announces Data Presentations at 16th World Conference on Lung Cancer September 6-9, 2015
September 04, 2015 at 06:03 AM EDT
Clovis Oncology (NASDAQ: CLVS) today announced that rociletinib, the company's oral targeted covalent (irreversible) mutant-selective ...